FDA Approved: ORILISSA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ORILISSA (elagolix) submitted by AbbVie, likely updating labeling and/or indications based on additional data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis
• Uterine Fibroids

Drugs mentioned

• Orilissa (elagolix)

Snippet

SUPPL AP for ORILISSA (ELAGOLIX)